Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 26 July

Grady Wulff
July 26, 2024

Morning Bell 26 July

Sam Kanaan
July 26, 2024

Morning Bell 25 July

Grady Wulff
July 25, 2024

Morning Bell 24 July

Grady Wulff
July 24, 2024

Morning Bell 23 July

Sam Kanaan
July 23, 2024

Morning Bell 22 July

Grady Wulff
July 22, 2024

Weekly Wrap 19 July

Grady Wulff
July 19, 2024

Morning Bell 19 July

Sam Kanaan
July 19, 2024

Morning Bell 18 July

Sam Kanaan
July 18, 2024

Morning Bell 17 July

Grady Wulff
July 17, 2024

Morning Bell 16 July

Grady Wulff
July 16, 2024

Morning Bell 15 July

Grady Wulff
July 15, 2024